{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:49:30Z","timestamp":1790412570888,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jcf.2023.01.007","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T17:45:40Z","timestamp":1674150340000},"page":"256-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-8990","authenticated-orcid":false,"given":"Daniel H","family":"Tewkesbury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Athwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowland J","family":"Bright-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-1055","authenticated-orcid":false,"given":"Andrew M","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-4431","authenticated-orcid":false,"given":"Peter J","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.jcf.2023.01.007_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"10212","key":"10.1016\/j.jcf.2023.01.007_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.01.007_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.01.007_bib0004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.01.007_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.01.007_bib0006","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jcf.2023.01.007_bib0007","series-title":"Acute liver failure in a patient with cystic fibrosis taking triple combination modulator","author":"Sharma","year":"2021"},{"key":"10.1016\/j.jcf.2023.01.007_bib0008","series-title":"Kaftrio, summary of product characteristics","year":"2020"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.007_bib0009","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MCP.0000000000000824","article-title":"Emerging clinical perspectives in cystic fibrosis liver disease","volume":"27","author":"Athwal","year":"2021","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"10.1016\/j.jcf.2023.01.007_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.16749","article-title":"Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis","volume":"55","author":"Scott","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.007_bib0011","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.007_bib0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota","volume":"8","author":"Fiorotto","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jcf.2023.01.007_bib0013","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bbadis.2017.07.023","article-title":"Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium","volume":"1864","author":"Strazzabosco","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jcf.2023.01.007_bib0014","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","author":"Dana","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.007_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.01.007_bib0016","series-title":"Assessment report","year":"2020"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:09Z","timestamp":1761601689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1569199323000085"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}